DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03045523 (ClinicalTrials.gov)	January 2017	26/1/2017	A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis	A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis Harbouring One F508del CFTR Mutation and a Second Gating (Class III) Mutation	Cystic Fibrosis	Drug: GLPG2222 150 mg q.d.;Drug: GLPG2222 300 mg q.d.;Drug: Placebo	Galapagos NV	NULL	Completed	18 Years	99 Years	All	37	Phase 2	Australia;Belgium;Czechia;Germany;Ireland;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03045523
(ClinicalTrials.gov)

January 2017

26/1/2017

A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis

A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis Harbouring One F508del CFTR Mutation and a Second Gating (Class III) Mutation

Cystic Fibrosis

Drug: GLPG2222 150 mg q.d.;Drug: GLPG2222 300 mg q.d.;Drug: Placebo

Galapagos NV

NULL

Completed

18 Years

99 Years

All

Phase 2

Australia;Belgium;Czechia;Germany;Ireland;United Kingdom